The world’s largest health care products manufacturer has agreed to pay for its mistakes.

Earlier this week, Johnson & Johnson (J&J) agreed to pay $22.9 million to settle a class action lawsuit claiming it investors about quality-control failures that led to recalls, including the largest recall of over-the-counter children’s medicine in U.S. history.

The investor plaintiffs claimed J&J and its executives made misleading statements about the recalls, and as a result, they suffered stock losses after more details about the recalls became public. 

“The proposed settlement is a favorable recovery for the class especially when viewed in light of the significant risks posed by continued litigation,” stated the filing, which J&J submitted on Monday.

As part of the settlement, J&J will make no admission of wrongdoing. The settlement would cover buyers of J&J shares between Oct. 14, 2008, and July 21, 2010.

Read Bloomberg for more information.

For more pharmaceutical-related stories from InsideCounsel, read:

Walgreens reaches $80 million settlement over painkillers

FDA allows continued sale of generic Opana painkiller

FDA issues warning about shortened cancer drug name

FDA considering petition to protect biologic medications’ patents

Generic-drug makers sue brand-name companies for product samples

Novartis cancer drug not innovative enough for patent, India Supreme Court rules

No wider recall for glass-tainted generic Lipitor

Pfizer settles Chantix suits for $273 million